Volition Achieves 95% Early-Stage Cancer Detection in 81-Patient Trial
Volition's Capture-Seq™ blinded validation cohort of 81 subjects achieved 94% sensitivity for stage I cancers, 96% for stage II and 95% overall specificity. The technology targets a combined $36 billion early cancer detection and MRD market, with active licensing discussions underway.
1. Validation Cohort Results
Volition conducted a blinded validation study on 81 subjects (59 cancer patients, 22 healthy controls) and achieved stage I detection at 94% (17/18), stage II at 96% (26/27), stage III at 100% (2/2) and stage IV at 91% (10/11). Overall sensitivity across all stages was 93% (55/59) with 95% specificity (21/22) in controls.
2. Capture-Seq™ Technology and IP
Capture-Seq™ physically enriches and bioinformatically purifies plasma samples to yield over 99% pure circulating tumor DNA for analysis. Volition has filed multiple patents to protect this novel two-step methodology focusing on circulating cell-free nucleoproteins.
3. Commercial Outlook and Licensing
The company projects a $23 billion human multi-cancer early detection (MCED) market and a $13 billion minimal residual disease (MRD) market, totaling $36 billion in addressable revenue. Volition is in active discussions with large liquid biopsy and diagnostic companies to license and accelerate development of Capture-Seq™.
4. Next Steps and Development
Volition plans to validate these results in larger cohorts and pursue clinical utility for early cancer detection and treatment monitoring. The technology’s potential extends to human and veterinary diagnostics, complementing the existing Nu.Q® product portfolio.